Outcome of plasma lipid profile in patients switching from Atripla® to Eviplera® compared to continuing on Atripla® (EfaRiLipidomics)

Fundació Hospital Vall Hebron Institut de Recerca0 个研究点开始时间: 2015年7月10日最近更新: 2017年4月3日

试验速览

暂无简介。

•- Patients aged 18 years or above
•- Patients infected with HIV-1
•- Patients in treatment with Atripla for at least the last six months.
•- Patients with virologic suppression ( RNA -HIV <50 copies / ml ) for at least the last six months .
•- Fertile Women must use a double barrier contraceptive method
•- Voluntary signature of the informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 28
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•- Any acute or chronic disease (besides the chronic infection for HIV 1) that could interfere in the lipidomic analysis
•- Pregnant or nursing women
•- Abuse of alcohol or other drugs
•- BMI > 25
•- Use of drugs that may affect lipid metabolism ( lipid lowering drugs , steroids ... )
•- Patients unable to understand the protocol of the study or any other condition that in opinion of the investigator could compromise the fulfillment of the protocol
•- History or presence of allergy to any of the study drugs or their components

发起方

Fundació Hospital Vall Hebron Institut de Recerca